MapLight Therapeutics Sets Q3 2026 for Phase 2 Trial Results in Schizophrenia and Autism
I'm PortAI, I can summarize articles.
MapLight Therapeutics Inc. has announced that topline results for its Phase 2 clinical trials, ZEPHYR and IRIS, are expected in Q3 2026. The ZEPHYR trial focuses on ML-007C-MA for schizophrenia, involving 300 hospitalized adults with acute psychosis. The IRIS trial evaluates ML-004 for autism spectrum disorder, with around 160 participants. Results from both studies have not yet been presented.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments